Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
Hemophagocytic LymphohistiocytosisThis study aimed to investigate the efficacy and safety of different doses of ruxolitinib as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).
Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic...
Nonneoplastic ConditionRATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of hemophagocytic lymphohistiocytosis cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more hemophagocytic lymphohistiocytosis cells. A donor stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Cyclosporine and methotrexate may stop this from happening. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by a donor stem cell transplant works in treating patients with hemophagocytic lymphohistiocytosis.
Etoposide in the First-line Treatment of Adult EBV-HLH
Hemophagocytic Lymphohistiocytosishis study aimed to investigate the efficacy of etoposide as the first line therapy for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
ChidamideHemophagocytic LymphohistiocytosisChidamide combines with VP-16 and methylprednisolone in HLH
L-DEP as an Initial Treatment for EBV-HLH
Hemophagocytic LymphohistiocytosisThis study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as an initial treatment for Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.
Trial of DA-EPOCH Regimen for NHL With HLH
NHL With Hemophagocytic LymphohistiocytosisThe major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic lymphohistiocytosis
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
Hemophagocytic LymphohistiocytosisThis is a phase I study of TQ05105 tablets in subjects with Hemophagocytic Lymphohistiocytosis.TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.
Ruxolitinib Combined With Dexamethasone for HLH
Hemophagocytic LymphohistiocytosisA protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.
Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated...
Hemophagocytic LymphohistiocytosisThis observational study is designed to provide a better understanding of the potential use of IFNγ and IFNγ-inducible chemokines as markers of HLH disease activity and prognosis, and of the potential of IFNγ as a therapeutic target in M-HLH.
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis...
Hemophagocytic LymphohistiocytosesThis observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.